Royce & Associates LP Has $21.63 Million Stock Holdings in Envista Holdings Corporation $NVST

Royce & Associates LP lifted its position in Envista Holdings Corporation (NYSE:NVST) by 11.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 996,147 shares of the company’s stock after acquiring an additional 103,312 shares during the quarter. Royce & Associates LP’s holdings in Envista were worth $21,626,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Assetmark Inc. grew its stake in shares of Envista by 1.4% in the 4th quarter. Assetmark Inc. now owns 46,273 shares of the company’s stock worth $1,005,000 after acquiring an additional 659 shares in the last quarter. Allworth Financial LP grew its stake in shares of Envista by 75.4% in the 4th quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock worth $39,000 after acquiring an additional 776 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Envista by 31.3% in the 4th quarter. GAMMA Investing LLC now owns 3,281 shares of the company’s stock worth $71,000 after acquiring an additional 783 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Envista by 35.3% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,041 shares of the company’s stock worth $62,000 after acquiring an additional 793 shares in the last quarter. Finally, IFP Advisors Inc grew its stake in shares of Envista by 102.9% in the 4th quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock worth $46,000 after acquiring an additional 1,071 shares in the last quarter.

Wall Street Analyst Weigh In

NVST has been the subject of several recent analyst reports. Mizuho upped their target price on shares of Envista from $24.00 to $27.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 10th. Piper Sandler reiterated a “neutral” rating and issued a $25.00 target price (up from $21.00) on shares of Envista in a research note on Friday, February 6th. Zacks Research lowered shares of Envista from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Morgan Stanley increased their price target on shares of Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Friday, April 24th. Finally, William Blair upgraded shares of Envista from a “hold” rating to an “outperform” rating in a research report on Friday, February 6th. Six investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.83.

Envista Price Performance

NVST opened at $23.52 on Wednesday. The firm has a market cap of $3.83 billion, a P/E ratio of 57.37, a PEG ratio of 1.47 and a beta of 0.92. The firm has a 50-day moving average of $25.51 and a 200 day moving average of $24.38. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.44. Envista Holdings Corporation has a fifty-two week low of $17.03 and a fifty-two week high of $30.42.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.05. Envista had a net margin of 2.41% and a return on equity of 7.11%. The business’s revenue for the quarter was up 14.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, research analysts expect that Envista Holdings Corporation will post 1.43 EPS for the current year.

Envista Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.